Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 213-224 , August 2007

Cytoprotective Agents Used in the Treatment of Patients With Cancer

  • William P. Hogle

      Affiliations

    • Corresponding Author InformationAddress correspondence to William P. Hogle, RN, MSN, OCN®, 9100 Babcock Blvd, Pittsburgh PA 15237

References 

  1. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3335
  2. Ethyol (amifostine) package insert. Gaithersberg, MD: MedImmune Oncology, Inc; 2005;September
  3. Dorr RT. Radioprotectants: pharmacology and clinical applications of amifostine. Semin Radiat Oncol. 1998;8(suppl 1):10–13
  4. Vincent M, Bramwell V, Moran LA, et al. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Curr Oncol. 2000;7:149–161
  5. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19–38
  6. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  7. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head and neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005;63:985–990
  8. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: randomized phase II study. J Clin Oncol. 2000;18:2226–2233
  9. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 2002;29(suppl 19):80–83
  10. Buntzel J, Kuttner K, Frohlich D, et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505–509
  11. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  12. Buntzel J, Micke O, Adamietz FA, et al. Intravenous amifostine during chemoradiotherapy for head and neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys. 2006;64:684–691
  13. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:72–77
  14. Amrein PC, Clark JR, Supko JG, et al. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005;104:1418–1427
  15. Saurel C. A phase I/II trial of induction chemotherapy followed by concomitant docetaxel with concomitant boost radiotherapy (CBR) and amifostine for advanced head and neck cancer. Proc Am Soc Clin Oncol. 2006;[abstr 15525]. Available at www.asco.org.
  16. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101–2112
  17. DiPaola R, Rodriguez R, Goodin S, et al. Ethyol and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther. 1998;1:11–17
  18. Akhtar S, Haider K, Bradshaw D, et al. Use of weekly one hour paclitaxel (P) infusion with dose escalation for recurrent or resistant cancers, using amifostine (AF) as a cytoprotector. Proc Am Soc Clin Oncol. 2000;[abstr 838]. Available at www.asco.org.
  19. Mitchell RB. Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 1998;[abstr 1906]. Available at www.asco.org.
  20. Illiano A, Barletta E, Di Marino V, et al. Triplet chemotherapy combination with carboplatin (CBDCA), paclitaxel (TAX), and gemcitabine (GEM) plus amifostine (AMF) support in advanced NSCLC. Proc Am Soc Clin Oncol. 2000;[abstr 2075]. Available at www.asco.org.
  21. Hartmann JT, Knop S, Fels LM, et al. The use of reduced dose of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide based chemotherapy in patients with solid tumors. Anticancer Drugs. 2000;11:1–6
  22. Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR-2721 and cisplatin. Int J Radiat Oncol Biol Phys. 1989;16:1201–1204
  23. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin and vinblastine for metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol. 1996;1913–1921
  24. Bokemeyer C, Hartmann JT, Fels L. Amifostine protects against early cisplatin induced renal damage and enhances CD34+ cell numbers for PBSC collection. Proc Am Soc Clin Oncol. 1997;[abstr 166]. Available at www.asco.org.
  25. Breier S, Lebedinsky C, Pelayes L, et al. Amifostine, cisplatin and vinorelbine in non-small cell lung cancer. Proc Am Soc Clin Oncol. 1997;[abstr 1664]. Available at www.asco.org.
  26. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer. 1988;61:2192–2195
  27. Moore DH. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel- induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:4207–4213
  28. Hilpert F, Stahle A, Tome O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy–a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Cancer Care. 2005;13:797–805
  29. Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007;24:[abstr]
  30. National Cancer Institute. Gynecologic Cancer Intergroup (GCIG) Clinical Trials. Available at. http://ctep.cancer.gov/resources/gcig/activetrials.html. (accessed November 22, 2006).
  31. Gelmon K, Eisenhower E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999;10:3038–3047
  32. Kanat O, Evrensel T, Baran I, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20:237–245
  33. Lorusso D, Ferrandina G, Greggs S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14:1086–1093
  34. Openshaw H. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res. 2004;10:461–467
  35. Ndubisi BU, Guthrie T, Benrubi G, et al. A phase II open-label study to evaluate the use of amifostine (Ethyol) in reversing chemotherapy-induced peripheral neuropathy (PN) in cancer patients-preliminary findings. Proc Am Soc Clin Oncol. 1999;[abstr 2326]. Available at www.asco.org
  36. Zinecard (dexrazoxane) package insert. New York, NY: Pfizer Inc; 2005;December
  37. Loerzel VW, Dow KH. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs. 2003;7:557–562
  38. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745–752
  39. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117–127
  40. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–1332
  41. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333–1340
  42. Marty M, Espie M, Llombart A, et al. A phase III study to investigate the cardioprotective potential of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients undergoing anthracycline-based chemotherapy. 27th Breast Cancer Symposium. 2004;[abstr/poster 5052]. December 8-11, San Antonio, TX
  43. Lima MV, Ferreira FV, Macedo FY, et al. Histologic changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol. 2007;59:643–650
  44. Burkert H. Clinical overview of mesna. Cancer Treat Rev. 1983;10(suppl A):175–181
  45. Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev. 1983;10(supp A):33–43
  46. Cox PJ, Abel G. Cyclophosphamide cystitis (Studies aimed at its minimization). Biochem Pharmacol. 1979;28:3499–3502
  47. Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep. 1979;63:501–505
  48. Bryant BM, Jarman M, Ford HT, et al. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet. 1980;2:657-559
  49. Andriole GL, Sandlund JT, Miser JS, et al. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol. 1987;5:799–803
  50. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol. 1999;27:64–71
  51. Steiling H, Werner S. Fibroblast growth factors: key players in epithelial morphogenesis, repair, and cytoprotection. Curr Opin Biotech. 2003;14:533–537
  52. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  53. Brizel D, Le Q, Rosenthal D, et al. Phase 2 study of recombinant human keratinocyte growth factor (RHuKGF) in head and neck cancer treated with standard (SRT) or hyperfractionated irradiation (HRT) and concurrent chemotherapy (CT). Proc Am Soc Radiol Oncol. 2002;[abstr 2128]. Available at www.astro.org
  54. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006;24:5194–5200
  55. Miller AL. Therapeutic considerations of L-glutamine: a review of the literature. Alt Med Rev. 1999;4:239–248
  56. Smith RJ. Glutamine metabolism and its physiological importance. J Parent Enter Nutr. 1999;14(suppl 4):94S–99S
  57. Lebow BI, Souba WW. Glutamine. World J Surg. 2000;24:1503–1513
  58. Medina MA. Glutamine and cancer. J Nutr. 2001;131(suppl 9):2539S–2542S
  59. Jebb SA, Osborne RJ, Maughan TS, et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine. Br J Cancer. 1994;70:732–735
  60. Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving 5-flourouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 1999;22:258–261
  61. Anderson PM, Schroeder G, Skubitz KM, et al. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998;83:1433–1439
  62. Decker-Baumann C, Buhl K, Frohmuller S, et al. Reduction of chemotherapy-induced side effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer. 1999;35:202–207
  63. Peterson DE, Petit RG. Oral mucositis incidence and severity reduced with AES-14. results of a phase III pivotal trial in patients with breast cancer [poster]. Presented at 1st Annual Chicago Supportive Oncology Conference (CSOC); October 6-8, 2005: Chicago, IL.
  64. Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000;46:535–539
  65. Klimberg VS, Rubio I, Kaufmann Y, et al. Effect of glutamine on radiation morbidity in breast conservation therapy is associated with a novel protein marker. 27th Breast Cancer Symposium. 2004;[abstr 4037]. December 8-11, San Antonio, TX
  66. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
  67. Cancer Care Ontario Guidelines. The role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer. Available at. http://www.cancercare.on.ca/pdf/pebc5-8s.pdf (accessed November 22, 2006).
  68. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(suppl):2026–2046

PII: S0749-2081(07)00056-3

doi: 10.1016/j.soncn.2007.05.006

Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 213-224 , August 2007

Article Tools